What are the treatment options for atrial fibrillation (Afib)?

Atrial Fibrillation Treatment

Primary Treatment Strategy: Rate Control Plus Anticoagulation

For most patients with atrial fibrillation, initial management should focus on rate control combined with anticoagulation based on stroke risk, as this approach is non-inferior to rhythm control for mortality and morbidity while avoiding the adverse effects and hospitalizations associated with antiarrhythmic drugs. 1, 2

---

Anticoagulation Strategy (First Priority)

Stroke Risk Assessment

• Calculate the CHA₂DS₂-VASc score immediately: Congestive heart failure (1 point), Hypertension (1 point), Age ≥75 years (2 points), Diabetes (1 point), prior Stroke/TIA/thromboembolism (2 points), Vascular disease (1 point), Age 65-74 years (1 point), Sex category female (1 point) 1

Anticoagulation Recommendations

• Initiate oral anticoagulation for all patients with CHA₂DS₂-VASc score ≥2 1, 3
• Consider anticoagulation for score of 1 4
• Direct oral anticoagulants (DOACs)—apixaban, dabigatran, edoxaban, or rivaroxaban—are preferred over warfarin due to lower intracranial hemorrhage risk 1, 4
• Use full standard doses of DOACs unless specific dose-reduction criteria are met 1
• For apixaban specifically: 5 mg twice daily, or 2.5 mg twice daily if patient meets ≥2 of these 3 criteria: age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL 1

Warfarin Management (When DOACs Contraindicated)

• Warfarin is required for mechanical heart valves or moderate-to-severe mitral stenosis 1, 5
• Target INR 2.0-3.0 for atrial fibrillation 5
• Monitor INR weekly during initiation, then monthly when stable 1, 5

Critical Anticoagulation Principles

• Continue anticoagulation according to stroke risk regardless of whether the patient is in sinus rhythm or atrial fibrillation 1, 3
• Do not use bleeding risk scores to decide whether to start or withhold anticoagulation 1
• Avoid combining anticoagulants with antiplatelet agents unless specifically indicated (e.g., acute coronary syndrome) 1
• Aspirin alone or aspirin plus clopidogrel are not recommended for stroke prevention in atrial fibrillation 4

---

Rate Control Strategy (Second Priority)

First-Line Rate Control Agents

For patients with preserved ejection fraction (LVEF >40%):

• Beta-blockers (metoprolol, atenolol) or non-dihydropyridine calcium channel blockers (diltiazem 60-120 mg TID or 120-360 mg extended release; verapamil 40-120 mg TID or 120-480 mg extended release) are first-line 1, 3
• These agents provide rapid onset and effectiveness even during high sympathetic tone 3

For patients with reduced ejection fraction (LVEF ≤40%):

• Use beta-blockers and/or digoxin (0.0625-0.25 mg daily) 1, 3
• Avoid diltiazem and verapamil due to negative inotropic effects and risk of hemodynamic compromise 1, 3

Rate Control Targets

• Lenient rate control (resting heart rate <110 bpm) is acceptable initially unless symptoms require stricter control 1, 3
• Strict control (resting heart rate <80 bpm) is reserved for patients with persistent symptoms despite lenient control 1

Combination Therapy

• Digoxin plus beta-blocker or calcium channel blocker provides better control at rest and during exercise if monotherapy is inadequate 1
• Digoxin should not be used as monotherapy in active patients as it only controls rate at rest and is ineffective during exercise 4

Special Populations

• For COPD or active bronchospasm: use diltiazem or verapamil; avoid beta-blockers, sotalol, and propafenone 1
• For postoperative atrial fibrillation: beta-blocker or non-dihydropyridine calcium channel blocker 1
• For high catecholamine states (acute illness, post-operative, thyrotoxicosis): beta-blockers are preferred 1

---

Rhythm Control Strategy (Selective Use)

Indications for Rhythm Control

• Consider rhythm control for: symptomatic patients despite adequate rate control, younger patients, new-onset atrial fibrillation, or hemodynamic instability 1, 3, 4
• The landmark AFFIRM trial demonstrated that rhythm control offers no survival advantage over rate control and causes more hospitalizations and adverse drug effects 3, 4, 2

Cardioversion Approach

Immediate electrical cardioversion required for:

• Hemodynamic instability (hypotension, acute heart failure, ongoing chest pain) 1, 3, 4

Scheduled cardioversion (electrical or pharmacological):

• If atrial fibrillation duration >48 hours or unknown: require 3 weeks of therapeutic anticoagulation before cardioversion and at least 4 weeks after 1, 4
• Continue anticoagulation long-term based on stroke risk factors regardless of rhythm status 1

Pharmacological Cardioversion Options

• For patients without structural heart disease: flecainide or propafenone 1, 3
• For patients with structural heart disease or reduced ejection fraction: amiodarone 1, 3
• Amiodarone IV (300 mg diluted in 250 mL 5% glucose over 30-60 minutes) for emergency or hemodynamic instability 1

Antiarrhythmic Drug Selection for Maintenance

Algorithm based on cardiac structure:

• No structural heart disease: Flecainide, propafenone, or sotalol (lowest toxicity risk) 1, 4
• Coronary artery disease without heart failure: Sotalol 1
• Heart failure or LVEF ≤40%: Amiodarone or dofetilide only (other agents carry proarrhythmic risk) 1, 4
• Hypertension without left ventricular hypertrophy: Flecainide or propafenone 1
• Hypertension with left ventricular hypertrophy: Amiodarone 1

Critical caveat: Amiodarone carries significant organ toxicity risks and should be reserved for refractory cases or patients with contraindications to other agents 4

---

Catheter Ablation

• Consider catheter ablation as second-line therapy when antiarrhythmic drugs fail to control symptoms 1, 3
• May be considered as first-line therapy in selected patients with paroxysmal atrial fibrillation 1, 3
• For patients with heart failure and reduced LVEF, catheter ablation may improve outcomes 4
• AV node ablation with pacemaker implantation should be considered in patients unresponsive to intensive rate and rhythm control therapy 3

---

Special Clinical Scenarios

Wolff-Parkinson-White Syndrome with Pre-excited Atrial Fibrillation

• If hemodynamically unstable: immediate DC cardioversion 1
• If stable: IV procainamide or ibutilide 1
• Never use AV nodal blockers (adenosine, digoxin, diltiazem, verapamil, beta-blockers, amiodarone) as they can accelerate ventricular rate and precipitate ventricular fibrillation 1
• Catheter ablation of accessory pathway is definitive treatment 1

Heart Failure with Atrial Fibrillation

• Consider rhythm control, as atrial fibrillation may be contributing to decompensation 1
• For permanent atrial fibrillation with severe symptoms and heart failure: AV node ablation combined with cardiac resynchronization therapy 3, 4

---

Common Pitfalls to Avoid

• Underdosing or inappropriately discontinuing anticoagulation increases stroke risk 1
• Most strokes occur after warfarin is stopped or when INR is subtherapeutic 2
• Failing to continue anticoagulation after cardioversion in patients with stroke risk factors 1
• Using digoxin as sole agent for rate control in paroxysmal atrial fibrillation or active patients 1, 4
• Performing catheter ablation without prior trial of medical therapy (except in selected first-line cases) 1
• Withdrawing anticoagulation in patients with clinically silent recurrences of atrial fibrillation while on antiarrhythmic drugs 3
• Using class I antiarrhythmic drugs in patients with ischemia or structural heart disease due to proarrhythmic risk 6